## Molly A Silvers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/260454/publications.pdf

Version: 2024-02-01

1163117 1588992 8 10 490 8 citations g-index h-index papers 10 10 10 1014 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Using a novel NQO1 bioactivatable drug, betaâ€lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 83-88.	1.7	24
2	The NQO1 bioactivatable drug, $\hat{l}^2$ -lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. Journal of Biological Chemistry, 2017, 292, 18203-18216.	3.4	72
3	A member of the Phosphate transporter 1 (Pht1) family from the arsenicâ€hyperaccumulating fern <i>Pteris vittata</i> is a highâ€affinity arsenate transporter. New Phytologist, 2016, 209, 762-772.	7.3	135
4	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell, 2016, 30, 940-952.	16.8	104
5	Crystal Structure of Carboxyltransferase from Staphylococcus aureus Bound to the Antibacterial Agent Moiramide B. Biochemistry, 2016, 55, 4666-4674.	2.5	14
6	NQO1 Bioactivatable Drugs Enhance Radiation Responses. , 2016, , 225-252.		1
7	Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and theirÂmechanistic insights. European Journal of Medicinal Chemistry, 2016, 122, 1-16.	<b>5.</b> 5	65
8	Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, $\hat{l}^2$ -lapachone. Scientific Reports, 2015, 5, 17066.	3.3	50
9	Design, Synthesis, and Antibacterial Properties of Dual-Ligand Inhibitors of Acetyl-CoA Carboxylase. Journal of Medicinal Chemistry, 2014, 57, 8947-8959.	6.4	25
10	Design and Synthesis of a Dualâ€Ligand Inhibitor for Acetylâ€CoA Carboxylase. FASEB Journal, 2013, 27, 806.3.	0.5	O